Fig. 4.
BIP-V5 inhibits Bax activation in bleomycin-induced pneumopathy and bleomycin-treated A549 cells. (A) The expression of the Bax-activated form of mouse bleomycin-induced pneumopathy homogenate lung on day 7. (B) The expression of Bax-activated form of A549 cells under BLM treatment. A549 cells were treated with normal saline or BLM (120 mU/ml) for 24 h. BIP-V5 (200 µM) was pre-dosed 1 h before the administration of saline or BLM. Data were collected from three separate experiments and are expressed as the mean±s.e.m. *P<0.05, **P<0.01. TCL, total cell lysate; IP, immunoprecipitation.